MEDICINES CONTROL COUNCIL
|
|
|
- Noah Norton
- 6 years ago
- Views:
Transcription
1 MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/3.1.2/14 INGELHEIM A39/34/0605 A39/34/0606 A39/34/0607 A39/34/0608 AFRICA AFRICA AFRICA AFRICA 41/11.10/0215 RECKITT BENCKISER METACAM 20 mg/ml FOR CATTLE, PIGS AND HORSES NICOTINELL FRUIT 2 mg COATED CHEWING GUM NICOTINELL FRUIT 4 mg COATED CHEWING GUM NICOTINELL MINT 2 mg COATED CHEWING GUM NICOTINELL MINT 4 mg COATED CHEWING GUM GAVISCON LIQUISHOT 41/21.10/0523 SERONO SA OVITRELLE 250 µg/0,5 ml 42/26/0608 PHARMACARE LIMITED ASPEN CARBOPLATIN 50 mg 42/26/0609 PHARMACARE LIMITED ASPEN CARBOPLATIN 150 mg 42/26/0610 PHARMACARE LIMITED ASPEN CARBOPLATIN 450 mg 42/20.1.1/0247 PHARMACARE LIMITED ASPEN AZITHROMYCIN IV Each 1,0 ml solution contains: MELOXICAM 20,0 mg NICOTINE 2,0 mg NICOTINE 4,0 mg NICOTINE 2,0 mg NICOTINE 4,0 mg Each sachet contains: SODIUM ALGINATE 500,0 mg Each 0,5 ml solution contains: CHORIOGONADOTROPIN ALFA 250,0 µg Each 5,0 ml vial contains: CARBOPLATIN 50,0 mg Each 15,0 ml vial contains: CARBOPLATIN 150,0 mg Each 45,0 ml vial contains: CARBOPLATIN 450,0 mg AZITHROMYCIN MONOHYDRATE AZITHROMYCIN 500,0 mg 12.64_Notification_of Apr12_v1.docx June 2012 Page 1 of 5
2 42/21.5.1/0310 XIXIA 42/21.5.1/0311 XIXIA 42/21.5.1/0312 XIXIA PREDNISOLONE 120 PREDNISOLONE 500 PREDNISOLONE HEMISUCCINATE 120,0 mg HEMISUCCINATE 500,0 mg HEMISUCCINATE 1 000,0 mg 42/7.1.3/0352 PHARMACARE LIMITED TRANDOPRESS 0,5 mg Each capsule contains: TRANDOLAPRIL 0,5 mg 42/20.1.1/0641 GULF DRUG COMPANY GULF CEFOTAXIME 2 g CEFOTAXIME SODIUM CEFOTAXIME 2,0 g 42/7.5/0805 PHARMACARE LIMITED VATICOL XL FLUVASTATIN SODIUM FLUVASTATIN 80,0 mg 42/7.1.3/0947 RANBAXY SA IRBELO 75 IRBESARTAN 75,0 mg 42/7.1.3/0948 RANBAXY SA IRBELO 150 IRBESARTAN 150,0 mg 42/7.1.3/0949 RANBAXY SA IRBELO 300 IRBESARTAN 300,0 mg 42/7.1.3/0950 RANBAXY SA RAN IRBESARTAN 75 IRBESARTAN 75,0 mg 42/7.1.3/0951 RANBAXY SA RAN IRBESARTAN 150 IRBESARTAN 150,0 mg 42/7.1.3/0952 RANBAXY SA RAN IRBESARTAN 300 IRBESARTAN 300,0 mg 42/26/0965 XIXIA 42/26/0966 XIXIA MYLAN CARBOPLATIN 150 MYLAN CARBOPLATIN 450 CARBOPLATIN 150,0 mg CARBOPLATIN 450,0 mg 42/2.9/0967 PHARMACARE LIMITED TRAMASPEN 50 mg Each capsule contains: 42/21.12/1096 ASTRAZENECA 43/2.6.5/0039 TRINITY PHARMA (PTY) 43/2.6.5/0040 TRINITY PHARMA (PTY) EVERDEX 1 mg RISPEVON 1 RISPEVON 2 TRAMADOL HYDROCHLORIDE 50,0 mg ANASTROZOLE 1,0 mg RISPERIDONE 1,0 mg RISPERIDONE 2,0 mg 12.64_Notification_of Apr12_v1.docx June 2012 Page 2 of 5
3 43/2.6.5/0041 TRINITY PHARMA (PTY) 43/2.6.5/0042 TRINITY PHARMA (PTY) 43/26/0046 XIXIA 43/20.1.1/0062 ORCHID SA 43/20.1.1/0063 ORCHID SA 43/26/0068 XIXIA 43/20.1.1/0221 BRIMPHARM SA (PTY) RISPEVON 3 RISPEVON 4 MYLAN GEMCITABINE 1 g ORCHID CEFUROXIME 250 mg ORCHID CEFUROXIME 500 mg MYLAN GEMCITABINE 200 mg ZEEMIDE 500 mg 43/11.4.3/0545 PHARMACARE LIMITED ASPEN PANTOPRAZOLE 20 43/11.4.3/0546 PHARMACARE LIMITED ASPEN PANTOPRAZOLE 40 43/20.2.8/0570 AUROBINDO PHARMA 43/20.2.8/0571 AUROBINDO PHARMA 43/2.5/0823 TRINITY PHARMA (PTY) 43/2.5/0824 TRINITY PHARMA (PTY) 43/2.5/0825 TRINITY PHARMA (PTY) 43/2.5/0826 TRINITY PHARMA (PTY) VUDERIT 30 mg VUDERIT 40 mg EPIMATE 25 EPIMATE 50 EPIMATE 100 EPIMATE 200 RISPERIDONE 3,0 mg RISPERIDONE 4,0 mg GEMCITABINE GEMCITABINE 1,0 g CEFUROXIME AXETIL CEFUROXIME 250,0 mg CEFUROXIME AXETIL CEFUROXIME 500,0 mg GEMCITABINE GEMCITABINE 200,0 mg AZITHROMYCIN DIHYDRATE AZITHROMYCIN 500,0 mg SESQUIHYDRATE PANTOPRAZOLE 20,0 mg SESQUIHYDRATE PANTOPRAZOLE 40,0 mg STAVUDINE 30,0 mg STAVUDINE 40,0 mg TOPIRAMATE 25,0 mg TOPIRAMATE 50,0 mg TOPIRAMATE 100,0 mg TOPIRAMATE 200,0 mg 43/11.4.3/1001 NYCOMED PANTOLOC OTC SESQUIHYDRATE PANTOPRAZOLE 20,0 mg 43/1.2/1015 ZYDUS HEALTHCARE SA ZYDUS ESCITALOPRAM 10 mg ESCITALOPRAM OXALATE EQUIVALENT TO ESCITALOPRAM 10,0 mg 12.64_Notification_of Apr12_v1.docx June 2012 Page 3 of 5
4 43/7.1.3/1044 AUROBINDO PHARMA 43/7.1.3/1045 AUROBINDO PHARMA 43/7.1.3/1046 AUROBINDO PHARMA 43/7.1.3/1047 AUROBINDO PHARMA 44/20.1.1/0316 BIOTECH LABORATORIES (PTY) 44/34/0391 CIPLA MEDPRO (PTY) 44/34/0392 CIPLA MEDPRO (PTY) 44/8.1/0550 NOVO NORDISK (PTY) 44/8.1/0551 NOVO NORDISK (PTY) 44/8.1/0552 NOVO NORDISK (PTY) 44/13.9.1/0632 ADCOCK INGRAM LIMITED BIQURETIC 10/ BIQURETIC 20/ AURO QUINAPRIL CO 10/ AURO QUINAPRIL CO 20/ KANAMYCIN 1 g BIOTECH SOLVENT FOR DOCELEX 20 SOLVENT FOR DOCELEX 80 NOVOSEVEN 1 mg NOVOSEVEN 2 mg NOVOSEVEN 5 mg XAMIOL GEL QUINAPRIL 10,0 mg QUINAPRIL 20,0 mg QUINAPRIL 10,0 mg QUINAPRIL 20,0 mg Each ampoule contains: KANAMYCIN SULPHATE KANAMYCIN 1 000,0 mg ETHANOL 13,0 % m/v ETHANOL 13,0 % m/v (rfviia) 1,0 mg (rfviia) 2,0 mg (rfviia) 5,0 mg Each gram contains: CALCIPOTRIOL HYDRATE CALCIPOTRIOL 50,0 µg BETAMETHASONE DIPROPIONATE BETAMETHASONE 0,5 mg 45/20.2.8/0111 MYLAN RILOVIA 200/50 LOPINAVIR 200,0 mg RITONAVIR 50,0 mg 12.64_Notification_of Apr12_v1.docx June 2012 Page 4 of 5
5 45/20.2.8/0112 MYLAN TENEMINE TENOFOVIR DISOPROXIL FUMARATE 300,0 mg EMTRICITABINE 200,0 mg 45/20.2.8/0169 MYLAN EFRIN EFAVIRENZ 600,0 mg 45/20.2.8/0336 MYLAN RILOVIA 100/25 LOPINAVIR 100,0 mg RITONAVIR 25,0 mg 45/20.2.8/0538 MACLEODS SA MACLEODS LAMIVUDINE 150 MS MANDISA HELA REGISTRAR OF MEDICINES 12.64_Notification_of Apr12_v1.docx June 2012 Page 5 of 5
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 07/3.1.2.2/23 NOVARTIS SA
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 06/17.1.6/07 AFRIVET LOGISTICS
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 42/2.5/0453 ZYDUS HEALTHCARE
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) A05/11.5/08 A38/20.1.1/0406
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/7.5/0281 PHARMACARE LIMITED
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/5.1/09 INGELHEIM 08/5.1/10
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 47/26/0920 SANOFI-AVENTIS
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 41/20.1.1/0039 SCP MYLAN
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/20.1.2/0204 BIOTECH 36/20.1.2/0205
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 30/2.10/0392 TEVA TEVA BACLOFEN
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5
Abiraterone Tablet 250 mg Q4 2015 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Q4 2014 Alendronic Acid Tablet 70 mg Available Amisulpride Tablet 50 ; 100 ; 200 ; 400 mg Available
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 July 2011 No. 4761
GOVERNMENT GAZETTE OF THE REPUBLIC OF N$4.00 WINDHOEK - 26 July 2011 No. 4761 CONTENTS Page GOVERNMENT NOTICE No. 122 Registration of certain medicines: Medicines and Related Substances Control Act, 2003...
PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6
Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$2.00 WINDHOEK - 3 June 2011 No. 4726 CONTENTS Page GOVERNMENT NOTICE No. 71 Medicines and Related Substances Control Act, 2003: Registration of certain medicines...
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 14 August 2013 No. 5263
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 14 August 2013 No. 5263 CONTENTS Page GOVERNMENT NOTICES No. 211 No. 212 Request for submission of name of pharmacist for nomination for
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 February 2013 No. 5142
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 26 February 2013 No. 5142 CONTENTS Page GOVERNMENT NOTICES No. 30 Notification of registration of certain medicines: Medicines and Related
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories
PAGE 1 OF 7 Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, New Categories A Maximum Reimbursable Price (MRP) or Pharmacare Reimbursement Price (PRP) has been established for
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$5.60 WINDHOEK - 31 July 2012 No. 5003
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$5.60 WINDHOEK - 31 July 2012 No. 5003 CONTENTS Page GOVERNMENT NOTICES No. 186 Cancellation of certain medicines: Medicines and Related Substances Control
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved
Product Name Strength Dosage Form Therapeutic Area Dossier Status Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved Alendronate Sodium 10/70mg Tablets Osteoporosis Approved Anastrozole
Marketing authorisations granted in September 2012
PL 00037/0648 03/09/2012 ABBOTT LABORATORIES LIMITED LEVELANZ 250 MG FILM-COATED TABLETS LEVETIRACETAM 250 MILLIGRAMMES POM PL 00037/0649 03/09/2012 ABBOTT LABORATORIES LIMITED LEVELANZ 500 MG FILM-COATED
Kern Pharma Portfolio 2014
Kern Pharma Portfolio 2014 DOSSIERS DEVELOPED DURING 2013-2014 ARIPIPRAZOL (ODT) 10mg, 15mg tablets CHONDROITIN SULPHATE 400mg capsules ( well established use ) DEXKETOPROFEN TROMETAMOL 25mg, tablets DULOXETIN
State of Industry Readiness for the New Demand Following the New Treatment Guidelines
JOINT MEDICINES PATENT POOL & WHO SATELLITE ON BRIDGING THE NEW TREATMENT GAP: WHAT WILL IT TAKE? State of Industry Readiness f the New Demand Following the New Treatment Guidelines Louis J. Riceberg,
Product List Finished Dosage Forms (FDF) B2B Business
Product List 2017 Finished Dosage Forms (FDF) B2B Business Anaesthetics Dermatology Lidocaine Lidocaine and Prilocaine Dexmedetomidine Hydrochloride Anti-Infectives Amoxicillin Trihydrate and Potassium
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS
SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
Supplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited
LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad,
BULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015
BULLETIN # 84 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 22, 2015 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
Approved by TAC Order to be given within 1 month-date
Approved by TAC Order to be given within 1 month-date 01.10.2018 Sr.No 1 TAB DICLOFENAC 50 MG 2 CEFOTAXIM 500 INJET 3 Inj. Ceftriaxone 500mg Vial 4 Promethazine Inj.25 mg/ml 2 ml Amp 5 Inj. Diclofenac
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs
Pharmacy Benefact A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS Number 723 February 2018 Pan-Canadian Select Molecule Price Initiative for Generic Drugs Alberta Drug Benefit List prices
MICROMEDEX(R) Healthcare Series Integrated Index
MICROMEDEX(R) Healthcare Series Integrated Index This volume has expired. Product will stop functioning in 13 days. Install the current volume now. Drug Information DRUGDEX DRUG EVALUATIONS cause of ABACAVIR
Thank you for your request for information that has been processed under reference number
Corporate Development Contact us: dhft.foi@nhs.net Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: 01332 265500 Minicom: 01332 785566 www.derbyhospitals@nhs.uk Follow us on Twitter @DerbyHospitals
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ZOLOFT (sertraline hydrochloride) tablets, for oral use This list does not imply that the products on this chart are interchangeable or have the
TLS HEALTH Product list up-dated 2017 (Origin: Portugal)
TLS HEALTH Product list up-dated 2017 (Origin: Portugal) 1 Alendronic acid 70 mg tablet 4 units 2 Amlodipine 10 mg tablet 20,60 units 3 Amlodipine 5 mg tablet 20,60 units 5 Aripiprazole 10 mg tablet 14,
YES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
Free Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference. Product Number API Test product Dose/ mg Manufacturer Country of manufacture Country
Advance Notification of Amendments to the March 2017 Drug Tariff
Advance Notification of Amendments to the March 2017 Drug Tariff ADDITIONS Part I - Drugs And Preparations Special Container Drug Qty Price Acetylcysteine 600mg capsules 30 39.95 A Caffeine citrate 50mg/5ml
Price Changes advised by Pharmac As at 12 June 2015
s advised by Pharmac New to be available ex Manufacturer from 12th of preceding month. From Wholesale from date of supplier support which could vary. Product Supplier Schedule % + or - 01 Jun 15 31 Oct
NB Drug Plans Formulary Update
Bulletin #984 October 31, 2018 NB Drug Formulary Update Drug product updates included in this bulletin: Drug product additions - New generic products will be reimbursed up to the category Maximum Allowable
TABLETS & CAPSULES. 8 Artemether + Lumafentarine Tablet (24 Tablet ) and Candesartan Tablet 8mg,16mg and 32 mg
TABLETS & CAPSULES Sr. No. Name of the product Strength 1 6-Mercaptopurine Tablets 50mg 2 Acetazolamide Tablet 250 mg 3 Al2O3 + Mg(OH)2 chewable Tablet 200 mg/200 mg 4 Allopurinol Tablet 100 mg 5 Ambroxol
Innovative Products Available. OTC Products Available
Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood
Ontario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes September 2017 Effective September 28, 2017 Drug Programs Policy and Strategy Branch
Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications
This document is scheduled to be published in the Federal Register on 12/01/2017 and available online at https://federalregister.gov/d/2017-25920, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
YES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
DT Description Price Category Price change
Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining
ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY
South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5
Each hard gela n capsule contains: Acebrophylline 100 mg. Each film coated tablet contains Aceclofenac IP 100 mg
1 S.NO NAME OF PRODUCT COMPOSITION PLANT CERTIFICATION 1 Acebrophylline Capsules 2 Aceclofenac Tablets IP 100mg 3 Aceclofenac Sustained Release Tablets 200mg 4 Aceclofenac & Paracetamol Tablets 5 Amlodipine
BULLETIN # 78. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on July 17, 2014
BULLETIN # 78 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on July 17, 2014 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
Updates to the Alberta Drug Benefit List. Effective July 1, 2018
Updates to the Alberta Drug Benefit List Effective July 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
Advance Notification of Amendments to the August 2018 Drug Tariff
Advance Notification of Amendments to the August 2018 Drug Tariff ADDITIONS Zero Discount Brivaracetam 100mg tablets Brivaracetam 25mg tablets Brivaracetam 50mg tablets Brivaracetam 75mg tablets Maraviroc
LIST OF DRUGS DURING 2004
LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
Updates to the Alberta Drug Benefit List. Effective December 1, 2018
Updates to the Alberta Drug Benefit List Effective December 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
HIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
Clinical Study Report Synopsis
Clinical Study Report Synopsis Skin Irritation Test of LEO 80185 gel (calcipotriol hydrate plus betamethasone dipropionate) in healthy Japanese subjects Design of trial: A phase 1, national, single-centre,
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
28 February 2017 TENDER RESULTS PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Status for some products included in the 2015/16 Invitation to Tender, d 6 November 2015 and
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
28 February 2017 TENDER RESULTS PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Status for some products included in the 2015/16 Invitation to Tender, d 6 November 2015 and
Update on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
+91-8071678267 Biovaxia Pharma http://www.biovaxia.com/ We are engaged in the specified business of manufacturer, supplier, trader & exporter of Pharmaceutical Tablet and Injections. Offered medicinal
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
Updates to the Alberta Drug Benefit List. Effective September 1, 2018
Updates to the Alberta Drug Benefit List Effective September 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Oncology supportive medicine list (formulary) 2016
Oncology supportive medicine list (formulary) 2016 Who we are Glencore Medical Scheme (referred to as 'the Scheme"), registration number 1253, is a non-profit organisation, registered with the Council
Chapter 5 ~ Infections
Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy
MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
Response to Day - 75 Comments:PT/H/0403/ /E/ P DRUG PRODUCT ESCITALOPRAM TABLETS
3.2.P DRUG PRODUCT ESCITALOPRAM TABLETS ANNEXURE - 3.2.P.5.1 AMENDED SECTION FOR DRUG PRODUCT SPECIFICATION 3.2.P.5 CONTROL OF DRUG PRODUCT (Escitalopram 5mg, 10mg, 15mg & 20mg Tablets). 3.2.P.5.1 SPECIFICATIONS
Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015
Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible
List of changes in Out-Patients Formulary
List of changes in Out-Patients Formulary Change in prescriber criteria Alpha Tocopheryl (Vitamin E) suspension 100mg/mL, tablets 50-150mg, tablets 670mg Atorvastatin tablets Bezafibrate tablets 400mg
Information for Vermont Prescribers of Prescription Drugs DUZALLO (lesinurad and allopurinol) Tablets
Information for Vermont Prescribers of Prescription Drugs DUZALLO (lesinurad and allopurinol) Tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy
List of Products Approved By Drugs Control Organization, Jaipur Sr. No. Name of Product Tablets Biological
List of Products Approved By Drugs Control Organization, Jaipur Sr. No. Name of Product Tablets Biological 1 Vitamin B Complex Tablets N.F.I.( Therapeutic) 2 Vitamin B Complex Tablets N.F.I. (Prophylactic)
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
PRAC recommendations on signals
3 April 2018 1 EMA/PRAC/136563/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 5-8 March 2018 PRAC meeting This document provides an overview of the recommendations adopted by the
The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
PBS PRICE INCREASES - AUGUST 2014 SCHEDULE
Price increase review - general PBS benzylpenicillin 600 mg injection, 1 x 600 mg vial 1775K, 3398W, BenPen 3.84 4.38 3486L benzylpenicillin 3 g injection, 1 x 3 g vial 2647H, 3399X, BenPen 6.60 7.55 3487M
Antiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
Updates to the Alberta Drug Benefit List. Effective February 1, 2018
Updates to the Alberta Drug Benefit List Effective February 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)